Cardiovascular

FDA approves Brilinta for ACSs

The U.S. Food and Drug Administration (FDA) has approved Brilinta (ticarelor) for reducing cardiovascular death and heart attack in patients with acute coronary syndromes (ACSs). Read more..


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Shares